Delivery Order SPE2DB22D9316-SPE2DB25FYP86
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tysabri 300 mg/15 ml vials. The contract, valued at $5,262.76 with a firm fixed-price arrangement, is scheduled for completion by August 18, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete directly in the open federal marketplace despite its small...
- The Defense Logistics Agency issued a delivery order valued at $21,483.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 ml vials. This firm fixed-price delivery order, awarded on November 20, 2025, with an ultimate completion date of December 12, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a $41,265.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Tysabri 300 mg/15 ml vials over a period ending on May 15, 2024. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,788.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tysabri 300 mg/15 ml vials. This firm fixed-price delivery order, awarded on June 2, 2025, with an ultimate completion date of June 24, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group is executing this order under its existing Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,627.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 mL vials. This firm fixed-price delivery order, issued on September 25, 2025, with an ultimate completion date of October 17, 2025, represents a specific procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency awarded a $52,627.70 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 ml vials. The contract, issued on June 4, 2025, with an ultimate completion date of June 26, 2025, carries no set-aside designation. This delivery order represents a near-term pharmaceutical supply requirement fulfilled through DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,262.76 to DMS Pharmaceutical Group Inc. on August 18, 2025, for the supply of TYSABRI 300 mg/15 ml vials. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, with performance taking place at the vendor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $5,262.76 for 4,569,009,975 units of Tysabri 300 mg/15 ml vials. The contract, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, carries no set-aside designation. Performance will be fulfilled from the vendor's Park Ridge facility. Tysabri is a biologic medication...
- On June 16, 2025, the Defense Logistics Agency (DLA), operating under the Medical Supply Chain division, awarded a delivery order valued at $21,051.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, is for the supply of TYSABRI 300 mg/15 ml vials. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $10,316.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the drug Tysabri, a 300 mg/15 ml vial, to support the recurring medical supply needs of military health facilities worldwide. This delivery order contract is part of a larger $499,999,999 indefinite delivery contract...
- SPE2DB22D9316Indefinite Delivery Contract
- SPE2DB22D9316-SPE2DB25FYP86Delivery Order
The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $10,525.54 for Tysabri 300 mg/15 ml vials on August 25, 2025. This firm fixed-price delivery order, which has an ultimate completion date of September 16, 2025, represents a specific pharmaceutical procurement to support federal healthcare operations. The award was made without set-aside designation, demonstrating the vendor's competitive positioning in open federal procurement markets. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026. Through this comprehensive IDC, the agency procures a wide range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. Tysabri, an immunosuppressant biologic used primarily for neurological conditions, exemplifies the specialized pharmaceutical products the contractor supplies as part of its critical role in the federal pharmaceutical supply chain supporting military health system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 8/25/25 |